Interestingly, the presence of concomitant EGFR mutations affects cultured KRAS-mutated NSCLC cells response to TKI, implying that EGFR-TKI may represent an effective treatment option against NSCLC with EGFR/KRAS co-mutation [29]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.